Your new experience awaits. Try the new design now and help us make it even better

REVIEW article

Front. Oncol.

Sec. Cancer Imaging and Image-directed Interventions

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1630424

MRI management of focal liver lesion: what a liver MRI beginner cannot fail to know

Provisionally accepted
Vincenza  GranataVincenza Granata1Roberta  FuscoRoberta Fusco1*Igino  SimonettiIgino Simonetti1Maria  Giovanna RigaMaria Giovanna Riga2Giuseppe  PellegrinoGiuseppe Pellegrino3Serena  CarrieroSerena Carriero4Gianpaolo  CarrafielloGianpaolo Carrafiello3,4Antonella  PetrilloAntonella Petrillo1Francesco  IzzoFrancesco Izzo1
  • 1G. Pascale National Cancer Institute Foundation (IRCCS), Naples, Italy
  • 2Department of Radiology, University of Padova, Padova, Italy
  • 3Diagnostic and Interventional Radiology, Università degli Studi di Milano, Milan, Italy
  • 4Diagnostic and Interventional Radiology Department, IRCCS Ca' Granda Fondazione Ospedale Maggiore Policlinico, Milan, Italy

The final, formatted version of the article will be published soon.

Magnetic Resonance Imaging (MRI) is currently recognized as the most suitable diagnostic tool in detection and characterization of focal liver lesions. Morphological and functional data allows, in different clinical scenarios, a high diagnostic performance for the characterization of even very small lesions and, therefore, improve patient management, reducing costs and times. Despite this premise, MRI should not be prescribed to all patients with focal liver lesions, but not only indications should be well known, but also individual patients should be considered. For different clinical scenario, according to the extrahepatic malignancy presence or known liver disease, MRI with contrast agent represents a useful diagnostic tool, although the choice of diagnostic tool will be subordinated to the operator experience, technology availability and patient specific characteristics. Standard protocol should include conventional sequences: T2-W sequences, T2-W sequences with fat suppression (FS), and in-op phase GRE T1 sequences and functional. Among functional, diffusion-weighted imaging (DWI) is mandatory, especially for detection of very small lesions, however diffusion restriction does not necessarily indicate that a lesion is malignant. Contrast-enhanced MR is the keystone of liver MR, especially for lesion categorization. Contrast agents can be classified as non-specific agents that distribute into vascular and extra-vascular extra-cellular spaces and specific agents acquired by hepatic cells, either taken up by Kupffer cells than by hepatocytes. The abbreviated protocol concept is subordinated to the idea that in less examination time it is possible to acquire all the information necessary for patient management using only part of the sequences that normally fall within a standardized protocol. Radiomics has emerged as a promising tool in the liver oncology field, particularly in colorectal liver metastases evaluation. To fully realize radiomics clinical value, it is essential to address several methodological hurdles, including the standardization of image acquisition and analysis workflows, rigorous validation across large and diverse patient cohorts. The aim of review, for a liver MRI beginner, is to provide a comprehensive overview of MRI management of focal liver lesion, with a focus on acquisition protocol, including abbreviated protocols, contrast media, and the capacity to report all relevant data to characterize focal liver lesions.

Keywords: Liver focal lesion, MRI, DWI, contrast agents, artificial intelligence, Radiomics

Received: 19 May 2025; Accepted: 19 Sep 2025.

Copyright: © 2025 Granata, Fusco, Simonetti, Riga, Pellegrino, Carriero, Carrafiello, Petrillo and Izzo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Roberta Fusco, r.fusco@istitutotumori.na.it

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.